Prediction of Response to Pegylated Interferon plus Ribavirin by IL28B Gene Variation in Patients Coinfected with HIV and Hepatitis C Virus

Pneda, Juan A.; Caruz, Antonio; Rivero, Antonio; Neukam, Karin; Salas, Irene; Camacho, Ángela; Palomares, José C.; Mira, José A.; Martínez, Antonio; Roldán, Carmen; de la Torre, Julián; Juan Macías
October 2010
Clinical Infectious Diseases;10/1/2010, Vol. 51 Issue 7, p788
Academic Journal
Background. Variation in the IL28B gene is associated with sustained virologic response (SVR) to pegylated interferon plus ribavirin in hepatitis C virus (HCV)-monoinfected patients with genotype 1. Data on other genotypes and on patients coinfected with human immunodeficiency virus (HIV) and HCV are more limited. We aimed to assess the predictive ability of variations in the single-nucleotide polymorphism rs12979860 for SVR in HIV/HCV-coinfected patients, regardless of HCV genotype. Methods. The rs12979860 genotype was determined by polymerase chain reaction in 154 patients who had received therapy against HCV with pegylated interferon plus ribavirin. Results. rs12979860 genotype was TT in 20 patients (13%), TC in 66 patients (43%), and CC in 68 patients (44%). Rates of SVR in patients with genotype CC and in those with genotype TC or TT, according to HCV genotype, were, respectively, 50% and 17% (P < .001) in patients with genotype 1, 80% and 25% (P=.027) in patients with genotype 4, and 93% and 77% (P=.115) in patients with genotype 3. The median (interquartile range) low-density lipoprotein cholesterol level in patients with rs12979860 CC was 89 mg/dL (73-120 mg/dL) versus 75 mg/dL (55-91 mg/dL) (P=.001) in those with TC or TT. Independent predictors of SVR were HCV genotype 2-3 (odds ratio [OR], 13.98; 95% confidence interval [CI], 4.87-40.1; P < .001), rs12979860 CC (OR, 5.05; 95% CI, 2.04-12.5; P ! .001), baseline plasma HCV RNA load of ⩽600,000 IU/mL (OR, 1.99; 95% CI, 1.18- 3.34; P=.009), and female sex (OR, 4.28; 95% CI, 1.08-16.96; P=.039). Conclusions. IL28B gene variations independently predict SVR in HIV/HCV-coinfected patients with HCV genotype 1 and non-genotype 1 HCV infection. The association between rs12979860 and plasma low-density lipoprotein cholesterol suggests that the system low-density lipoprotein ligand/receptor might be involved in the effect of this genotype.


Related Articles

  • Hepatitis C Virus Infection-Related Morbidity and Mortality among Patients with Human Immunodeficiency Virus Infection. Monga, Harpreet K.; Rodriguez-Barradas, Maria C.; Breaux, Katharine; Khattak, Kamran; Troisi, Catherine L.; Velez, Maria; Yoffe, Boris // Clinical Infectious Diseases;7/15/2001, Vol. 33 Issue 2, p240 

    Presents a study that discussed the morbidity and mortality of Hepatitis C virus (HCV) infection among patients with HIV virus infection. Factors that might promote progression of HCV-related chronic liver disease and HIV disease; Demographic characteristics, seroprevalence and baseline...

  • Current status and future directions in the management of chronic hepatitis C.  // Virology Journal;2012, Vol. 9 Issue 1, p57 

    The article presents a research which examines the several aspects related to current status and future directions in the management of chronic hepatitis C virus (HCV) which is endemic worldwide. It is reported that, the medical knowledge about the disease and its mechanisms is limited because...

  • Diagnosis and treatment of chronic hepatitis C infection. Patel, Keyur; Muir, Andrew J.; McHutchinson, John G. // BMJ: British Medical Journal (International Edition);4/29/2006, Vol. 332 Issue 7548, p1013 

    This article offers a breakdown of diagnostic and treatment options for chronic hepatitis C infections. The risk factors associated with hepatitis C include extensive liver damage and hepatic fibrosis. The disease may progress in numerous ways making it difficult to predict rates of the...

  • Monocyte Activation by Interferon α Is Associated With Failure to Achieve a Sustained Virologic Response After Treatment for Hepatitis C Virus Infection. Hartigan-O'Connor, Dennis J.; Lin, Din; Ryan, James C.; Shvachko, Valentina A.; Cozen, Myrna L.; Segal, Mark R.; Terrault, Norah A.; Lanier, Lewis L.; Manos, M. Michele; McCune, Joseph M. // Journal of Infectious Diseases;May2014, Vol. 209 Issue 10, p1602 

    Background. Interferon α (IFN-α) and ribavirin can induce a sustained virologic response (SVR) in some but not all hepatitis C virus (HCV)–infected patients. The mechanism of effective treatment is unclear. One possibility is that IFN-α differentially improves the functional...

  • Hepatitis C: Diagnosis and Treatment. WILKINS, THAD; MALCOLM, JENNIFER K.; SCHADE, ROBERT R. // American Family Physician;6/1/2010, Vol. 81 Issue 11, p1351 

    Hepatitis C, a common chronic bloodborne infection, is found in approximately 2 percent of adults in the United States. Chronic infection is associated with serious morbidity and mortality (e.g., cirrhosis, hepatocellular carcinoma). Testing for hepatitis C is recommended for at-risk...

  • The Impact of Interleukin 28b Gene Polymorphism on the Virological Response to Combined Pegylated Interferon and Ribavirin Therapy in Chronic HCV Genotype 4 Infected Egyptian Patients Using Data Mining Analysis. Khairy, Marwa; Fouad, Rabab; Mabrouk, Mahassen; El-Akel, Wafaa; Bakr Awad, Abu; Salama, Rabab; Elnegouly, Mayada; Shaker, Olfat // Hepatitis Monthly;Jul2013, Vol. 13 Issue 7, p1 

    Background: Chronic HCV represents one of the common causes of chronic liver disease worldwide with Egypt having the highest prevalence, namely genotype 4. Interleukin IL-28B gene polymorphism has been shown to relate to HCV treatment response, mainly in genotype1. Objectives: We aim to evaluate...

  • Peginterferon Plus Ribavirin for Chronic Hepatitis C in Patients With Human Immunodeficiency Virus. Gluud, Lise Lotte; Marchesini, Emanuela; Iorio, Alfonso // American Journal of Gastroenterology;Sep2009, Vol. 104 Issue 9, p2335 

    OBJECTIVES:The aim of this study was to assess the effects of peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus (HIV).METHODS:Trials were identified through manual and electronic searches. Randomized trials comparing peginterferon plus ribavirin...

  • A mutational shift from domain III to II in the internal ribosome entry site of hepatitis C virus after interferon–ribavirin therapy. Ogata, Kei; Kashiwagi, Takahito; Iwahashi, Jun; Hara, Koyu; Honda, Haruhito; Ide, Tatsuya; Kumashiro, Ryukichi; Kohara, Michinori; Sata, Michio; Watanabe, Hiroshi; Hamada, Nobuyuki // Archives of Virology;Aug2008, Vol. 153 Issue 8, p1575 

    We focused on the relationship between variation in the IRES of hepatitis C virus (HCV) genotype 1b and clinical outcome, since the internal ribosome entry site (IRES) has a comparatively low heterogeneity and it might be easy to find unique substitutions. Patients infected with HCV were...

  • Prospect of Individualized Medicine in Chronic Hepatitis C Therapy by Pharmacogenomics. Yuchi Hwang; Chunli Su; Ding-Shinn Chen; Pei-Jer Chen // Current Pharmacogenomics;Jun2006, Vol. 4 Issue 2, p157 

    Interferon-α and ribavirin combination therapy has been the current choice for treating chronic hepatitis C (CHC) patients. The treatment takes 6 to 12 months but the overall sustained response rate is only around 50% and often brings significant adverse effects to some patients. The...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics